Floatz logo

Heptanoin, Tri-

Glucose Metabolism Disease

University of Texas Southwestern Medical CenterSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Glucose Metabolism Disease cohort.

Asset / SponsorPhaseRating
Metformin
SINA Health Education and Welfare Trust
Phase 4BBB
Glargine
Federico II University
Phase 4BB
Exenatide
RenJi Hospital
Phase 4BB
Retrovir
Kirby Institute
Phase 4BB
Empagliflozin
SINA Health Education and Welfare Trust
Phase 4BB

View all 28 →

Same molecule, other indications

Heptanoin, Tri- is also rated in:

GLUT1 deficiency syndromeDormant
BB
Indicative · Phase 2
69 / 100
View asset →
encephalopathy due to GLUT1 deficiencyDormant
BB
Indicative · Phase 2
64 / 100
View asset →
Huntington diseaseDormant
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →